Mirum Pharmaceuticals (MIRM) Cost of Revenue (2023 - 2026)

Mirum Pharmaceuticals' Cost of Revenue history runs 4 years deep, the most recent figure standing at $28.8 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 25.14% year-over-year to $28.8 million; the TTM figure through Mar 2026 stood at $106.0 million (up 22.11% YoY), while the FY2025 annual figure was $100.2 million, up 22.78% from the prior year.
• Cost of Revenue was $28.8 million for Q1 2026 at Mirum Pharmaceuticals, up from $28.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $28.8 million in Q1 2026 to a low of $5.0 million in Q1 2023.
• Historically, Cost of Revenue has averaged $19.8 million across 4 years, with a median of $22.8 million in 2024.
• Biggest YoY gain for Cost of Revenue was 258.1% in 2024; the steepest drop was 8.95% in 2024.
• A 4-year view of Cost of Revenue shows it stood at $25.0 million in 2023, then fell by 8.95% to $22.8 million in 2024, then gained by 24.07% to $28.3 million in 2025, then rose by 1.91% to $28.8 million in 2026.
• The last three Cost of Revenue figures came in at $28.8 million (Q1 2026), $28.3 million (Q4 2025), and $25.5 million (Q3 2025), per Business Quant data.